Close

NICE announces launch of a new database to inform the prioritisation of European cancer research

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

BD Commits Expanding the Prefilled Flush...

Beckton Dickinson – BD is investing over $35mn in...

MHRA Wants Fast Patient Access to...

The medicines and healthcare products regulatory agency – MHRA...

Portable Digital Radiography for Hospitals, Ambulatory...

FUJIFILM Healthcare Americas Corporation, which happens to be a...

$12 M APAC AI For Society...

In a move that highlights the deepening commitment of Google...

The National Institute for Health and Clinical Excellence has launched a new database that will help with the identification and prioritisation of future cancer research across Europe.

The Database of Cancer Uncertainties has been developed through the Coordination of Cancer Clinical Practice Guidelines in Europe initiative. CoCanCPG is a consortium of 16 institutional partners from 11 countries and is funded by the European Commission.

Uncertainties around the evidence base used in guideline development are common, indeed, it is rare that all aspects of the management of a condition are supported by high-quality research evidence. In some circumstances, the research has not been done and even where it has been done it may be methodologically flawed or inconclusive.

The cancer uncertainties database will provide a tool to bring these uncertainties together and link into other initiatives such as the UK’s Database of Uncertainties about the Effects of Treatments – DUETs. The uncertainties will be prioritised with input from clinicians, patients, funders and researchers. The prioritised uncertainties can then be promoted to research funders and researchers across the EU. Tracking mechanisms will be developed to avoid duplication of effort and highlight relevant clinical trials that patients can participate in. The co-ordination will help to ensure that the available research funds are spent against identified priorities.

Latest stories

Related stories

BD Commits Expanding the Prefilled Flush Syringes in the US

Beckton Dickinson – BD is investing over $35mn in...

MHRA Wants Fast Patient Access to Innovative Medical Devices

The medicines and healthcare products regulatory agency – MHRA...

Portable Digital Radiography for Hospitals, Ambulatory Units

FUJIFILM Healthcare Americas Corporation, which happens to be a...

$12 M APAC AI For Society Initiative Launched by Google

In a move that highlights the deepening commitment of Google...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back